WO2005018531A3 - Compositions pharmaceutiques, composes azo-heterocycliques et procedes de fabrication et d'utilisation correspondants - Google Patents

Compositions pharmaceutiques, composes azo-heterocycliques et procedes de fabrication et d'utilisation correspondants Download PDF

Info

Publication number
WO2005018531A3
WO2005018531A3 PCT/RU2004/000331 RU2004000331W WO2005018531A3 WO 2005018531 A3 WO2005018531 A3 WO 2005018531A3 RU 2004000331 W RU2004000331 W RU 2004000331W WO 2005018531 A3 WO2005018531 A3 WO 2005018531A3
Authority
WO
WIPO (PCT)
Prior art keywords
azo
production
pharmaceutical compositions
heterocyclic compounds
kaspaz
Prior art date
Application number
PCT/RU2004/000331
Other languages
English (en)
Russian (ru)
Other versions
WO2005018531A2 (fr
Inventor
Alexander Vasiliev Ivashchenko
Alexey Petrovich Ilyin
Vladimir Vasilievich Kobak
Dmitri Vladimirovic Kravchenko
Alexander Viktorovich Khvat
Sergey Yevgenievich Tkachenko
Ilya Matusovich Okun
Original Assignee
Chemical Diversity Res Inst Lt
Alexander Vasiliev Ivashchenko
Alexey Petrovich Ilyin
Vladimir Vasilievich Kobak
Dmitri Vladimirovic Kravchenko
Alexander Viktorovich Khvat
Sergey Yevgenievich Tkachenko
Ilya Matusovich Okun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2003125938/04A external-priority patent/RU2259999C2/ru
Priority claimed from RU2003125936/04A external-priority patent/RU2248978C1/ru
Priority claimed from RU2003126299/04A external-priority patent/RU2251546C1/ru
Application filed by Chemical Diversity Res Inst Lt, Alexander Vasiliev Ivashchenko, Alexey Petrovich Ilyin, Vladimir Vasilievich Kobak, Dmitri Vladimirovic Kravchenko, Alexander Viktorovich Khvat, Sergey Yevgenievich Tkachenko, Ilya Matusovich Okun filed Critical Chemical Diversity Res Inst Lt
Publication of WO2005018531A2 publication Critical patent/WO2005018531A2/fr
Publication of WO2005018531A3 publication Critical patent/WO2005018531A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C07D475/14—Benz [g] pteridines, e.g. riboflavin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La composition pharmaceutique de l'invention manifeste une activité inhibitrice par rapport à la sérine protéinase (Kaspaz) et comprend un principe actif ayant la forme d'une quantité pharmaceutiquement acceptable d'un composé azo-hétérocyclique ayant la formule générale 1, 2 et 3, ou de leur sel, avec un acide, un hydrate ou un N-oxyde pharmaceutiquement acceptable.
PCT/RU2004/000331 2003-08-26 2004-08-25 Compositions pharmaceutiques, composes azo-heterocycliques et procedes de fabrication et d'utilisation correspondants WO2005018531A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
RU2003125938 2003-08-26
RU2003125936 2003-08-26
RU2003125938/04A RU2259999C2 (ru) 2003-08-26 2003-08-26 1-сульфонил-1,3-дигидроиндол-2-оны, фармацевтические композиции (варианты), способ их получения и применения
RU2003125936/04A RU2248978C1 (ru) 2003-08-26 2003-08-26 Фармацевтические композиции, способ их получения и применения
RU2003126299 2003-08-29
RU2003126299/04A RU2251546C1 (ru) 2003-08-29 2003-08-29 Замещенные 3-оксо-1,2,3,4-тетрагидрохиноксалины, фармацевтические композиции (варианты), способ их получения и применения

Publications (2)

Publication Number Publication Date
WO2005018531A2 WO2005018531A2 (fr) 2005-03-03
WO2005018531A3 true WO2005018531A3 (fr) 2005-05-12

Family

ID=34222197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2004/000331 WO2005018531A2 (fr) 2003-08-26 2004-08-25 Compositions pharmaceutiques, composes azo-heterocycliques et procedes de fabrication et d'utilisation correspondants

Country Status (1)

Country Link
WO (1) WO2005018531A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US9351974B2 (en) 2011-11-10 2016-05-31 OSI Pharmaceuticals, LLC Substituted pteridinones for the treatment of cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0509398A1 (fr) * 1991-04-15 1992-10-21 Hoechst Aktiengesellschaft Quinoxalines, procédé pour leur préparation et leur utilisation
EP0657166A1 (fr) * 1993-12-09 1995-06-14 Hoechst Aktiengesellschaft Composition contenant un quinixaline et un nucléoside
EP0708093A1 (fr) * 1994-10-19 1996-04-24 Hoechst Aktiengesellschaft Quinoxalines, procédé pour leur préparation et leur application
WO1997025986A1 (fr) * 1996-01-17 1997-07-24 Taiho Pharmaceutical Co., Ltd. Inhibiteurs d'epaississement de l'intima
WO2001002394A1 (fr) * 1999-07-01 2001-01-11 Geron Corporation Composes indole substitues et leur utilisation dans le traitement du cancer
WO2003008407A2 (fr) * 2001-07-17 2003-01-30 Sanofi-Synthelabo Derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0509398A1 (fr) * 1991-04-15 1992-10-21 Hoechst Aktiengesellschaft Quinoxalines, procédé pour leur préparation et leur utilisation
EP0657166A1 (fr) * 1993-12-09 1995-06-14 Hoechst Aktiengesellschaft Composition contenant un quinixaline et un nucléoside
EP0708093A1 (fr) * 1994-10-19 1996-04-24 Hoechst Aktiengesellschaft Quinoxalines, procédé pour leur préparation et leur application
WO1997025986A1 (fr) * 1996-01-17 1997-07-24 Taiho Pharmaceutical Co., Ltd. Inhibiteurs d'epaississement de l'intima
WO2001002394A1 (fr) * 1999-07-01 2001-01-11 Geron Corporation Composes indole substitues et leur utilisation dans le traitement du cancer
WO2003008407A2 (fr) * 2001-07-17 2003-01-30 Sanofi-Synthelabo Derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Catalog name: ChemDiv, Inc., Product Library, 25.04.2003, Chemical library, RN 442524-94-9 *
Catalog name: Interbioscreen Compound Library, 09.05.2003 RN381170-51-0 *
Catalog name: Interchim INtermediates, 09.07.2002, Chemical library RN 442524-95-0 *
DATABASE ACS [online] AGARWAL S. ET AL: "Synthesis and pharmacological screening of 1-(substituted acyl/arylalkyl/arylsulfonyl)-2-0x0-3-(phenylsulfonyl hydrazono)-5-substituted indoles", accession no. STN Database accession no. 104:243 *
DATABASE ACS [online] AKSEL'ROD ZH.I. ET AL: "Substituon and addition reaction in the alloxazine and isoalloxazine series", accession no. STN Database accession no. 80:3469 *
DATABASE ACS [online] KOZIOL J. ET AL: "Synthesis and properties of roseolumichromes and their covalent hydrates", accession no. STN Database accession no. 94:15677 *
DATABASE ACS [online] RUDZIT E.A. ET AL: "Study of allo-and isoalloxazines. LI. Synthesis and antimicrodbal activity allo- and isoalloxazines derivatives", accession no. STN Database accession no. 88:170100 *
DATABASE ACS [online] TUL'CHINSKAYA ET AL: "Study of allo-and isoalloxazines.LV. Synthesis and properties of 7-amino-substituted alloxazines", accession no. STN Database accession no. 95:187198 *
INDIAN DRUG, vol. 22, no. 12, 1985, pages 633 - 639 *
KHIMICO-FARMATSEVTICHESKII ZHURNAL, vol. 12, no. 1, 1978, pages 52 - 57 *
VITAM. VITAM.PREP, 1973, pages 92 - 111 *
ZESZYTY NAUKOWE-ACADEMIA ECONOMICZNA W POZNANIU, SERIA I:PRACE Z ZAKREZU TOWAROZNAWSTWA I CHEMII, vol. 80, 1978, pages 110 - 114 *
ZHOURNAL ORGANICHESKOI KHIMII, vol. 17, no. 5, 1981, pages 1039 - 1046 *

Also Published As

Publication number Publication date
WO2005018531A2 (fr) 2005-03-03

Similar Documents

Publication Publication Date Title
MY144209A (en) Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2006000371A3 (fr) Derives de pyrimidine
WO2006010546A3 (fr) Derives d'aryl-pyridine
WO2003063864A3 (fr) Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
WO2008046758A3 (fr) Dérivés d'imidazolone et d'imidazolidinone utilisés en tant qu'inhibiteurs de l'enzyme 11b-hsd1 pour le diabète
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
WO2006116733A3 (fr) Inhibiteurs des proteines kinases
TW200626558A (en) Indazolone derivatives
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
WO2004101528A3 (fr) Inhibiteurs de la gfat
WO2010136474A3 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
CA2499330A1 (fr) Nouvelles quinazolinones spiro-condensees et utilisation associee en tant qu'inhibiteurs de phosphodiesterase
CA2510853A1 (fr) Derives de pyrrolopyrimidine
WO2008067257A3 (fr) Inhibiteurs de l'enzyme diacylglycérol o-acyltransférase de type 1
WO2006077025A3 (fr) Morpholines en tant qu'agonistes de 5ht2c
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2006117211A3 (fr) Derives d'uree, procedes pour leur fabrication et utilisations de ces derives
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
SE9904413D0 (sv) Comminuted form
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
WO2004014868A8 (fr) Derives de pyrimidine 2,4-diones, utilises comme inhibiteurs de metalloproteinase matricielle
MY140164A (en) Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase